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Abstract
Background: The management of hepatocellular carcinoma (HCC) is limited by the lack of adequate screening
biomarkers and chemotherapy. In response, there has been much interest in tumor metabolism as a therapeutic
target. PCSK9 stimulates internalization of the LDL-receptor, decreases cholesterol uptake into hepatocytes and
affects liver regeneration. Thus, we investigated whether PCSK9 expression is altered in HCC, influencing its ability
to harness cholesterol metabolism.
Methods: Thirty-nine patients undergoing partial hepatectomy or liver transplantation for HCC were consented for
use of HCC tissue to construct a tissue microarray (TMA). The TMA was immunostained for PCSK9. Imagescope
software was used to objectively determine staining, and assess for pathological and clinical correlations. PCSK9 and
LDL receptor mRNA levels in flash-frozen HCC and adjacent liver tissue were determined by quantitative RT-PCR.
Serum PCSK9 levels were determined by ELISA.
Results: By immunohistochemistry, there was significantly lower expression of PCSK9 in HCC as compared to
adjacent cirrhosis (p-value < 0.0001, wilcoxon signed-rank test). Significantly greater staining of PCSK9 was present in
cirrhosis compared to HCC (p value <0.0001), and positivity (percentage of positive cells) was significantly greater in
cirrhosis compared to HCC (p-value < 0.0001). Conversely, significantly higher expression of LDL-R was present in
HCC as compared to the adjacent cirrhosis (p-value < 0.0001). There was no significant correlation of PCSK9 staining
with grade of tumor, but there were significant correlations between PCSK9 staining and stage of fibrosis, according to
spearman correlation test.
PCSK9 mRNA levels were relatively less abundant within HCC compared to adjacent liver tissue (p-value =0.08) and
normal control tissue (p-value =0.02). In contrast, serum PCSK9 levels were significantly increased among patients with
HCC compared to those with chronic liver disease without HCC (p-value =0.029). LDL receptor mRNA was consistantly
greater in HCC when compared to normal control tissue (p-value = 0.06) and, in general, was significantly greater in
HCC when compared to adjacent liver (p-value = 0.04).
Conclusions: The decreased expression of PCSK9 and conversely increased LDL-R expression in HCC suggests that
HCC modulates its local microenvironment to enable a constant energy supply. Larger-scale studies should be
conducted to determine whether PCSK9 could be a therapeutic target for HCC.
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Background
Hepatocellular carcinoma (HCC) is the third leading cause
of cancer death worldwide, with a 5-year median survival
of 8.9 % [1]. The incidence of HCC has been rising in the
Western world as hepatitis C and non-alcoholic steatohe-
patitis (NASH) cirrhosis gain prominence, and as the sur-
vival rate of cirrhotic patients improves [2–4]. Recent data
have indicated a 71 % increase in HCC incidence on this
basis [5]. An additional consideration is that liver disease
etiologies such as NASH can induce HCC without cirrho-
sis having developed [6].
Proprotein convertase subtilisin/kexin type 9, also known
as PCSK9, is a protein expressed extensively in the liver,
and plays an important role in cholesterol metabolism by
regulating LDL receptor levels. PCSK9 does so by enabling
a faster rate of lysosomal degradation of cell-surface LDL
(low-density lipoprotein) receptor, leading to decreased
LDL uptake and increased circulating cholesterol levels [7].
This protein has also been shown to stimulate liver regen-
eration [8]. Genome-wide expression changes have been
evaluated in the context of PCSK9 overexpression, demon-
strating changes in pro-oncogenic pathways involved in
the control of cell cycle, inflammation and stress response
[9]. More recently, Pcsk9(−/−) mice [10] were found to be
protected against liver metastases, with increased apoptosis
of metastatic cells and have a blunted response to liver re-
generation following hepatectomy [11].
Given the role of PCSK9 in hepatic cholesterol me-
tabolism and liver regeneration, this study aimed to
assess PCSK9 expression in HCC and to determine
whether PCSK9 protein is a potential therapeutic target
for HCC treatment paradigms.
Methods
Tissue microarray construction and immunostaining
Using the McGill University Health Centre Liver trans-
plant database, we established a list of patients having
undergone liver transplant or partial hepatectomy for
HCC. Only those patients who were eligible for liver
transplant (i.e. for HCC within Milan criteria: a single
tumor less than 5 cm in diameter, or less than/equal to 3
tumors less than 3 cm in diameter) or partial hepatec-
tomy for HCC in patients with well compensated liver
function (HCC that had arisen in the context of chronic
viral hepatitis or Child-Pugh A cirrhosis) were included
in the study. Thus, none of the patients had HCC beyond
Stage 2. Exclusion criteria were the use of transarterial
chemoembolization or chemotherapy prior to banking of
pathology specimens, as the resulting necrotic samples
would not appropriately reflect protein expression.
Patients were approached and consented for use of
their HCC tissue samples, with the ethics protocol hav-
ing been approved by the McGill University Health
Centre Institutional Review Board.
Slides of liver resections were reviewed by a liver path-
ologist (VM), and HCC and adjacent liver areas were
identified. The corresponding tissue blocks were marked
for use in the Tissue Microarray (TMA), and sample
cores were removed from the tissue blocks. These cores
were incorporated into a TMA using a microarrayer in-
strument. Once the tissue microarray was constructed, a
second pathologist (RA) confirmed the accuracy of the
HCC and cirrhosis tissue specimens.
Rabbit anti-sera raised against PCSK9 were produced
used as previously described [12]. Immunohistochemical
staining for PCSK9 was performed using the rabbit ABC
Immunostaining System (Santa Cruz Biotech). We add-
itionally permeabilized the cells with Triton 0.1 % in PBS
buffer and unmasked antigens by heat treatment with
10 mM sodium citrate buffer (pH 6.0). PCSK9 antibody
was applied to slides at 1:200 dilution.
Images of these slides stained for PCSK9 were scanned
at 20X magnification. These images were analyzed by
Aperio ImageScope software (Vista, CA). Labeling inten-
sity and percentage of positive cells (positivity) were
quantified using the Positive Pixel Count Algorithm ver-
sion 9.1. The pixel intensity reflected the amount of
antibody binding to PCSK9, and is a measure of bright-
ness, being proportional to the amount of light transmit-
ted through the slide.
The liver cancer (HCC) and adjacent cirrhosis tissue
of each individual tumor were analyzed with the positive
pixel count algorithm. A mouse-guided pen tool was
used to outline these areas within each TMA section.
The number of strong positive pixels ratio (NSR) was
used to compare the density of staining in liver cancer
and cirrhosis tissues. In order to normalize each sample
to the area under consideration, the number of strongly
labeled positive pixels was divided by the total number
of positive pixels. This generated a labeling intensity of
the HCC or cirrhosis cell type per unit area of tissue.
Using the various algorithms described above, we de-
termined differences in PCSK9 expression between HCC
and adjacent cirrhosis tissue. This was also correlated
with the following clinical parameters: grade of HCC,
stage of fibrosis, and etiology of liver disease (Hepatitis
C, Hepatitis B, alcoholic liver disease, non-alcoholic stea-
tohepatitis, and other).
PCSK9 and LDL-R receptor mRNA levels in HCC
RNA was isolated from samples of 6 fresh frozen
HCC tumors as previously described [13]. RT-PCR
was performed on the isolated RNA using PCSK9 or
LDL-receptor-specific primers (Life Technologies, NY.
Hs00545399 and HS00722989 respectively) and mRNA
abundance, relative to 18S and GAPDH (Life Technologies,
NY.HS00115509) expression, in the tumors and adjacent
liver parenchyma was measured. PCSK9 and LDL-receptor
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mRNA levels were also measured in facial closure biopsy
tissues, which served as control.
Serum PCSK9 levels in HCC patients
In a different patient cohort, serum samples were pro-
spectively obtained from 40 patients diagnosed with HCC,
36 patients with cirrhosis, and 6 apparently healthy con-
trol subjects. Serum PCSK9 levels were measured using
an in-house ELISA assay as previously described [14].
Levels were compared between the above subject cat-
egories. We also tested whether there was an associ-
ation between PCSK9 and alpha-fetoprotein (AFP)
levels and PCSK9 levels and tumor sizes using the
Spearman correlation.
Statistical analysis
All results are expressed as mean ± SD. Differences be-
tween pathological condition at any given time were
done by two tailed Student’s t-test. We also tested
whether there was an association between PCSK9 and
alpha-fetoprotein (AFP) levels and PCSK9 levels and
tumor sizes using the Spearman correlation. A p < 0.05
was considered statistically significant. The Kruskal–
Wallis one-way analysis was used for comparing more
than two variances.
Results
Forty patients with HCC consented to inclusion in the tis-
sue microarray portion of this study. Their demographic
and clinical characteristics are listed in Table 1. Of these,
there were 11 patients who had more than one tumor,
and these additional tumors were also incorporated
into the TMA.
PCSK9 immunohistochemistry
Most of the cirrhosis samples, which were obtained just ad-
jacent to the interface between tumor and cirrhotic back-
ground, stained strongly for PCSK9. Employing Wilcoxon
signed-rank test to compare PCSK9 staining of tumour and
those of adjacent cirrhosis, we found that there was signifi-
cantly lower expression of PCSK9 in the HCC samples as
compared to the adjacent cirrhosis with: a positivity of
0.72 ± 0.03 versus 0.89 ± 0.009 (p-value < 0.0001), total
intensity of positives of 30413022.89 ± 2916711.84 pixel
intensity versus 47844692.78 ± 3501425.25 pixel inten-
sity (p-value < 0.0001), total intensity of strong positives
of 244849.22 ± 30352.09 versus 591716 ± 95497.21 pixel
intensity (p-value < 0.0001), proportion of strong posi-
tives of 0.005 ± 0.0003 versus 0.011 ± 0.001 (p-value <
0.0001) (Fig. 1).
We also employed Wilcoxon signed-rank test to com-
pare LDL-R staining of tumour and those of adjacent
cirrhosis (Fig. 2), we found that there was significantly
higher expression of LDL-R in the HCC samples as
compared to the adjacent cirrhosis with: a positivity of
0.992 ± 0.001 versus 0.986 ± 0.002 (p-value = 0.013), total
intensity of positives of 184722732 ± 15287852.05 pixel
intensity versus 91021737 ± 8108288.90 pixel intensity
(p-value < 0.0001), total intensity of strong positives of
4329282 ± 887724.04 versus 1066570 ± 235470.9 pixel in-
tensity (p-value < 0.0001), proportion of strong positives
of 0.022 ± 0.004 versus 0.009 ± 0.002 (p-value < 0.0001).
We treated grade of tumor and stage of fibrosis as or-
dered values and employed spearman correlation test to
examine whether there were non-zero correlations be-
tween grade of tumor (or stage of fibrosis) and PCSK9
staining. We found that grade of tumor did not correlate
with PCSK9 staining (p-values > 0.30). There was
Table 1 Demographic and Clinical Characteristics of patients with HCC
Demographic/clinical characteristics Mean
Age 57.55 years
Sex 7/39 (18 %) female, 32/39 (82 %) male
Etiology of liver disease (N = 39) • Hepatitis B 14 (36 %)
• Hepatitis C 15 (38.5 %)
• Alcohol 3 (7.7 %)
• Non-Alcoholic Steatohepatitis 4 (5 %)
• α1-antitrypsin 1 (2.6 %)
• Hemochromatosis 1 (2.6 %)
• Sarcoidosis 1 (2.6 %)
Cirrhosis 33/39 (84.6 %)
Differentiation of HCC Poorly-differentiated: 6 (15.3 %)
Moderately-differentiated: 15 (38.5 %)
Well-differentiated: 18 (46.2 %)
Vascular invasion 8/39 (20.5 %)
Bhat et al. BMC Gastroenterology  (2015) 15:176 Page 3 of 10
therefore no difference in PCSK9 expression between
poorly and well-differentiated tumors (Fig. 3a).
On the contrary, we found that PCSK9 total intensity
of strong positives was present in more advanced stages
of fibrosis (p-value = 0.0008, Fig. 3b), as was the positiv-
ity (p-value = 0.001), and proportion of strong positives
(p-value = 0.03).
We employed the same spearman analyses to examine
the correlation between grade of tumor (or stage of fi-
brosis) and LDL-R staining. Similarly, we did not find
significant non-zero correlation between tumor grade
and LDL-R staining (p-values > 0.25). In addition, we
found that LDL-R total intensity of positives was nega-
tively correlated with stages of fibrosis (p-value = 0.02).
Fig. 1 Comparison of PCSK9 immunohistochemical staining in hepatocellular carcinoma and adjacent liver tissue. a Total intensity of positives of
30413022.89 ± 2916711.84 pixel intensity versus 47844692.78 ± 3501425.25 pixel intensity (p-value < 0.0001); (b) Total intensity of strong positives
of 244849.22 ± 30352.09 versus 591716 ± 95497.21 pixel intensity (p-value < 0.0001); (c) Positivity of 0.72 ± 0.03 versus 0.89 ± 0.009 (p-value < 0.0001); (d)
proportion of strong positives of 0.005 ± 0.0003 versus 0.011 ± 0.001 (p-value < 0.0001); (e) Representative core of hepatocellular carcinoma adjacent to
cirrhosis, stained with PCSK9 antibody; (f) Representative core of cirrhosis strongly staining with PCSK9 antibody
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Otherwise, we did not find significant non-zero correl-
ation between stages of fibrosis and LDL-R staining (p-
values > 0.13).
PCSK9 and LDL-receptor mRNA levels
The HCCs had less PCSK9 mRNA when compared to
matched adjacent tissue, although this did not reach statis-
tical significance (p-value = 0.08). There was also significant
reduction in PCSK9 expression seen in HCC tumors when
compared to controls (p-value =0.02) (Fig. 4a). LDL receptor
expression was consistently lower in facial closure liver biop-
sies when compared to HCC (p-value = 0.06) (Fig. 4b). In
contrast, LDL-receptor mRNA levels in adjacent liver tissue
were variable and were linked with LDL-receptor mRNA
levels in the matched HCC tumor tissue. Where LDL-
receptor mRNA was low in the HCC tumor the levels in the
adjacent liver was moderate to high (2 of 6 pairs). Con-
versely, when LDL-receptor mRNA levels in the HCC tumor
were high the levels were either below the level of detection
or low in the tumor adjacent liver (4 of 6 pairs). In general,
LDL-receptor mRNA expression was 33 % lower in HCC
adjacent liver tissue when compared to HCC (p-value =
0.04) but was greater than that in normal liver tissue (p-
value = 0.02) (Fig. 4b).
Serum PCSK9 levels
Serum samples of different patient populations were
tested for PCSK9 level, as detailed in Table 2. The average
age of this patient cohort was 59+/− 1.3 years, and 62 %
were male. The etiology of liver disease for the patients
with HCC was as follows: 15 with Hepatitis C, 6 with
Hepatitis B, 9 with alcoholic liver disease, and 10 with
Non-alcoholic steatohepatitis.
The etiology of liver disease for the patients without
HCC was as follows: 13 with Hepatitis C, 5 with Hepatitis
B, 2 with alcoholic liver disease, 9 with Non-alcoholic
steatohepatitis, 5 with cryptogenic cirrhosis, 1 with Pri-
mary sclerosing cholangitis and 2 with Primary biliary
cirrhosis.
As shown in Fig. 5, patients with HCC tended to have
higher serum PCSK9 levels (p-value =0.029). Additionally,
patients with cirrhosis had higher mean PCSK9 values as
compared to chronic liver disease patients without cirrho-
sis (p-value =0.048).
Discussion
The treatment of advanced HCC is currently limited,
with only the chemotherapeutic agent sorafenib proven
to yield some benefit. The therapeutic approach to ad-
vanced HCC has been rendered difficult by the variety
of pathways that can lead to hepatocarcinogenesis. Find-
ing metabolic targets that are common to all tumors, re-
gardless of the activated molecular pathway, would help
simplify the chemotherapeutic approach. In this study,
we elucidate the expression of PCSK9 and that of LDL-
R, the protein whose expression it modulates, in HCC.
We were interested in evaluating the expression of
PCSK9 in HCC, because PCSK9 is known to stimulate
liver regeneration after partial hepatectomy [8] and plays
an essential role in cholesterol metabolism. Moreover,
there has been limited study of tumor metabolism as a
potential therapeutic target for HCC. In our study, we
objectively found that by immunohistochemistry, PCSK9
was much less present in HCC than adjacent cirrhotic
liver tissue, independent of tumor grade. Conversely, we
discovered that LDL-R expression was significantly in-
creased within the tumors, whereas it was decreased in
the adjacent liver tissue. We confirmed the validity of
these immunohistochemical findings by performing
PCSK9 mRNA quantification of flash frozen samples,
where the same significant difference in expression
was seen. This suggests a HCC-derived modulation of
cholesterol metabolism to fuel growth, via PCSK9
Fig. 2 a No significant correlation of PCSK9 expression by immunohistochemistry with grade of tumor. b Significant correlation of PCSK9 expression
by immunohistochemistry with stage of fibrosis
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enhanced degradation of the LDL receptor (LDLR). Con-
sequently, lower PCSK9 expression potentially provides
HCC with a preferential phenotype to utilize cholesterol:
higher expression of LDLR in the tumor as compared to
the areas surrounding the tumor would increase LDL in-
ternalisation in the tumor, making LDL more available to
the cancer cells and facilitating cholesterol availability to
HCC. This enhanced metabolic potential due to preferen-
tial utilization of energy supplies because of a down-
regulation of metabolic machinery by the surrounding
tissue has been put forth in the context of other tumors
such as breast cancer [15, 16].
PCSK9 was initially identified as being highly expressed
in embryonic and mature mouse livers [8]. These investi-
gations revealed that PCSK9 was distinctly upregulated
(2.5 fold times normal) in the hepatocytes, peaking at day
2 after partial hepatectomy. PCSK9 expression peaked on
day 2, which is similar to the pattern of expression seen
with liver and intestinal apolipoprotein B (ApoB, part of
LDL) after hepatectomy. A second study of PCSK9-
Fig. 3 Comparison of LDL-receptor immunohistochemical staining in hepatocellular carcinoma and adjacent liver tissue (a) Total intensity of positives
of 184722732 ± 15287852.05 pixel intensity versus 91021737 ± 8108288.90 pixel intensity (p-value < 0.0001); (b) Total intensity of strong positives of
4329282 ± 887724.04 versus 1066570 ± 235470.9 pixel intensity (p-value < 0.0001); (c) Positivity of 0.992 ± 0.001 versus 0.986 ± 0.002 (p-value = 0.013);
(d) Proportion of strong positives of 0.022 ± 0.004 versus 0.009 ± 0.002 (p-value < 0.0001). (e) Representative core of hepatocellular carcinoma, strongly
staining with LDL-R antibody; (f) Representative core of cirrhosis staining with LDL-R antibody
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deficient mice further confirmed the critical role of PCSK9
in liver regeneration following partial hepatectomy [11].
PCSK9-deficient mice developed necrotic liver lesions fol-
lowing partial hepatectomy, rather than regeneration of
liver tissue. Such damage was prevented if the mice were
administered a high-cholesterol diet. The PCSK9-deficient
mice exhibited less lipid accumulation in hepatocytes, thus
indicating that the lack of PCSK9 prevents development
of hepatic steatosis. The overall conclusion of this study
was that PCSK9 deficiency could put patients at risk fol-
lowing hepatic damage [11]. In addition to our findings,
these data suggest the plausibility of PCSK9 as a metabolic
target in HCC.
PCSK9 is subject to downregulation by cholesterol
[17, 18], and upregulation by sterol regulatory element
binding proteins (SREBPs) [19], cholesterol biosynthesis
inhibitors [20], and cholestyramine [21]. This type of
regulation is analogous to that seen with other genes
implicated in cholesterol biosynthesis. Specifically, PCSK9
is regulated at the transcriptional level by SREBPs, which
also regulate other key genes in fatty acid synthesis
(SREBP-1c) and cholesterol metabolism (SREBP-2). In
fact, the promoter of PCSK9 contains an SREBP binding
site [20]. Fasting or cholesterol feeding inhibits SREBP-2
and leads to decreased PCSK9 mRNA expression in
mouse livers. Although we did not delve into this, it is
possible that HCC tumors have mutations in the above-
mentioned proteins, leading to dysregulated PCSK9
regulation.
In our study, tumors tended to have decreased PCSK9
expression, potentially indicating that they had acquired
the ability to harness the energy supply in the surround-
ing environment for further growth. It could be that the
upregulated expression of PCSK9, a protein that plays a
role in cholesterol metabolism, in the areas surrounding
tumor promotes cell and tumor growth by making chol-
esterol as a source of energy more available to the can-
cer cells. This increased energy supply provided by the
supporting tissue would lead to further tumor growth, a
theory that has been put forth in the context of other tu-
mors such as breast cancer [15, 16].
Our study findings also tie in nicely with PCSK9's role
in liver regeneration following partial hepatectomy. The
upregulation of PCSK9 in the liver tissue adjacent to the
HCC tumors possibly indicate that this protein plays a
permissive role in initiating dysplasia from hepatic pro-
genitor cells and promoting subsequent malignant growth.
This is based on the hepatic progenitor cell theory of
hepatocarcinogenesis [22, 23].
In our study, the systemic levels of PCSK9 did not cor-
relate well with the presence or absence of tumor. In the
literature, the reported mean values of human plasma
PCSK9 concentrations are quite variable, ranging from a
low of 80 ng/mL [24], 150 ng/mL [14] or 200 ng/mL
Fig. 4 a PCSK9 is less expressed in tumor as compared to adjacent liver parenchyma and control tissue, whereas b LDL-receptor mRNA is more
highly expressed in tumor tissue as compared to adjacent parenchyma and control tissue
Table 2 Clinical characteristics of patients whose serum was tested for PCSK9 levels. The patients with HCC had significantly higher
PCSK9 than healthy controls, as well as those with cirrhosis and chronic hepatitis
Clinical characteristics HCC (N = 40) Cirrhosis (N = 13) Chronic Hepatitis (N = 38) Healthy controls (N = 6)
Average PCSK9 (ng/mL) 91.6 78.3 69.2 92.1
Alphafetoprotein levels 30.1 N.A. N.A. N.A.
Average tumor diameter (SD) 5.64 (3.88) N.A. N.A. N.A.
SD = standard deviation, N.A. = not applicable
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[25] to a high of 4.1 mg/mL [26] or 6.1 mg/mL [27]. This
variability arises due to the different antibodies against
PCSK9 used in the various assays. The assay used in our
study has a mean of 77–80 ng/mL, meaning that the HCC
patients had a ~12 % higher value on average, which is not
significantly different from normal values. The half-life of
PCSK9 has been determined to be only 5 min in vivo [28],
which implies that the liver is continuously producing high
levels of PCSK9. However, at least based on our findings,
the ongoing malignant process in the liver with modulation
of PCSK9 levels locally has no impact systemically.
A principal limiting factor of our study is that the
HCC samples used came only from patients who were
eligible for liver transplant or hepatectomy. This means
that these cancers were either caught at an early stage or
were less aggressive. Thus, our findings need to be inter-
preted in this context of localized HCC tumors. It is dif-
ficult to confirm whether the etiology of liver disease has
an impact on expression (eg: fatty liver) given the low
numbers of cases. Also, dynamic changes in expression
cannot be assessed, given that this is a cross-sectional
study.
However, the data do look promising and correlate with
the literature. In recent years, there has been heightened
interest in the metabolism and cellular energetics of ma-
lignancies, and whether targeting this aspect could curtail
cancer growth [29, 30]. Modulation of tumor energy con-
sumption and metabolism with agents such as metformin
through the AMPK pathway has been shown to inhibit
breast cancer growth both in vitro and in vivo [31, 32]. It
is possible that the activity of PCSK9 could similarly be
modified with the recently developed PCSK9 monoclonal
antibodies [33] to impose caloric restriction to HCC tu-
mors. This phenomenon of metabolomic coupling has
been well described in papers pertaining to breast cancer.
In this model proposed by Lisanti et al., fibroblasts in the
stroma adjacent to breast cancer undergo aerobic glycoly-
sis (also known as the Warburg effect) [34, 35]. They thus
produce and secrete pyruvate and lactate that can be uti-
lized by adjacent breast epithelial cancer cells to supply
Fig. 5 Comparison of serum PCSK9 levels among patients with hepatocellular carcinoma versus those with cirrhosis or chronic liver disease
without cirrhosis, demonstrating: (a) Logistic fit of HCC by PCSK9 model, with serum levels of PCSK9 in HCC patients being significantly higher
than those in patients with cirrhosis or chronic liver disease (p-value =0.029); (b) Logistic fit of PCSK9 by HCC tumor diameter model, showing no
correlation between these two parameters; (c) Logistic fit of Cirrhosis by PCSK9 model, with serum levels of PCSK9 in patients with cirrhosis being
higher than those in patients without cirrhosis (p-value =0.048)
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and fuel the mitochondrial TCA cycle, oxidative phos-
phorylation, and ATP production within the cancer cell.
Conclusion
In conclusion, the decreased PCSK9 expression in HCC
is suggestive of alterations in cholesterol metabolism to
the benefit of liver tumor growth. This implies that HCC
tumors can modulate their local and adjacent micro-
environment, thus enabling better energy supply to fuel
tumor growth. These findings have interesting therapeutic
implications: modulation of PCSK9 could potentially be
therapeutically exploited with the newly-developed anti-
bodies to PCSK9 or targeted pharmaceuticals, thus chal-
lenging the metabolism of HCC and subduing its growth.
Thus, the advanced phase III clinical trial using PCSK9 in-
hibitors is in a better situation to assess long term safety,
and would register the incidence of many cancers includ-
ing liver [36]. This question is highly topical in this era of
tumor metabolism as a therapeutic target, and merits fur-
ther study.
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